Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.58 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739298 | 0.92 | FAAH (0.51) | FAAHSSTR4TRPV1ALDH1A1RAB9A | |
| SCHEMBL18335854 | 0.82 | FAAH (0.55) | FAAHTRPV1ALDH1A1RAB9A | |
| SCHEMBL6620132 | 0.80 | SSTR4 (0.59) | SSTR4 | |
| SCHEMBL5675472 | 0.79 | FAAH (0.72) | FAAHTRPV1ALDH1A1RAB9A | |
| SCHEMBL30408248 | 0.79 | FAAH (0.59) | FAAHTRPV1ALDH1A1RAB9A | |
| SCHEMBL19275676 | 0.79 | FAAH (0.59) | FAAHTRPV1ALDH1A1RAB9A | |
| SCHEMBL21618459 | 0.79 | FAAH (0.59) | FAAHTRPV1ALDH1A1RAB9A | |
| SCHEMBL19275674 | 0.79 | FAAH (0.59) | FAAHTRPV1ALDH1A1RAB9A | |
| SCHEMBL1954713 | 0.78 | FAAH (0.58) | FAAHTRPV1ALDH1A1RAB9A | |
| SCHEMBL4335228 | 0.78 | SSTR4 (0.51) | SSTR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556454-A1 | COMPOUNDS HAVING A SECONDARY OR TERTIARY HYDROXY OR HALIDE GROUP SEPARATED FROM A PRIMARY CARBAMATE GROUP BY THREE OR MORE CARBON ATOMS AND A METHOD OF MAKING THE SAME | Basf Corporation (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004041948-A1 | COMPOUNDS HAVING A SECONDARY OR TERTIARY HYDROXY OR HALIDE GROUP SEPARATED FROM A PRIMARY CARBAMATE GROUP BY THREE OR MORE CARBON ATOMS AND A METHOD OF MAKING THE SAME | BASF CORPORATION (US) | 2004-05-21 | — | — | WO | claimed |
| US-20040087738-A1 | Compounds having a secondary or tertiary hydroxy or halide group separated from a primary carbamate group by three or more carbon atoms and a method of making the same | BASF CORPORATION | 2004-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087738-A1 | Compounds having a secondary or tertiary hydroxy or halide group separated from a primary carbamate group by three or more carbon atoms and a method of making the same | HCRTR1, HRH4, HCRTR2 | FAAH 26/4885SSTR4 117/4885TRPV1 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.